New Drosophila screening lab further expands RxCelerate’s drug discovery and development capabilities

Cambridge, UK Wednesday 24th April 2024, 9AM GMT

RxCelerate is excited to launch our new fly screening service, further expanding the bespoke and flexible drug discovery and development services we offer.

Cambridge, UK, 24 April 2024: The new lab offers cutting-edge fly screening services, using the fruit fly Drosophila melanogaster as a powerful tool for investigating human diseases and testing novel therapeutics.

The fruit fly is a versatile, time- and cost-effective model system, widely used in biomedical research because of its genetic similarity to humans.

“Drosophila have been used in research for over a century. Their simplicity, quick generation times, and the fact that they share ~75% of the genes that cause human disease make them an excellent model system for both basic research and drug development”

“I’m excited to be part of the team establishing the fly lab, and I look forward to the value it will bring to our clients’ projects.”

Dr Nicole Dawney

Senior Scientist - Drosophila Genetics, RxCelerate

The new lab is designed to support a wide range of client needs, offering services from model identification and validation to small- and large-scale screening. With current projects ranging from neuroscience to oncology, RxCelerate works closely with clients to determine the most suitable Drosophila models for their research. Experiments are tailored to each project, allowing for flexible and responsive study designs. In addition, real-time data sharing ensures that clients remain fully involved in their projects throughout the screening process.

For further information, visit our Drosophila service page.

Notes for Editors

RxCelerate is an outsourced drug discovery and development company based in Cambridge, UK, founded in 2013. It has rapidly grown to become one of the leading providers of drug discovery and development services in the UK. RxCelerate operates a unique model, offering collaborative strategic thinking to clients to help design and execute every aspect of their research and development plans.

RxCelerate offers a comprehensive suite of services covering the entire discovery and development spectrum, including in silico design and discovery, antibody discovery, synthetic and medicinal chemistry, bioanalysis, in vitro services, preclinical services, and project management. Clients can also access RxCelerate’s proprietary platform technologies, including RxNfinity™ for rapid in silico screening, the Galaxy® platform for generating diverse ‘clinic-ready’ antibodies, and ProQuant® for precise bottom-up proteomics across diverse biological samples. The combination of integrated teams and unique technologies allows RxCelerate to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.

RxCelerate has a team of more than 100 employees based in 25,000 square feet of premium laboratory and office space in the Dorothy Hodgkin Building at the Babraham Research Campus, approximately five miles south of Cambridge, UK, as well as offices in Boston, MA.

For more information, please visit www.rxcelerate.com or contact us at info@rxcelerate.com.

Read More News